At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research (NASDAQ:ARWR) put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing assumptions."
But as Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss in the video below, those conservative pricing assumptions aren't nearly conservative enough. Pricing in China, at less than a third of the price in the U.S., would still result in over $800 billion to treat the 93 million people that are chronically infected with the virus. There's just no way the government or private payers could afford that much to cover one disease.
As a comparison, consider Gilead Sciences (NASDAQ:GILD), which offered Egypt a 99% discount for its hepatitis C drug Sovaldi. That's about where Arrowhead should expect to price its hepatitis B drug if it gets approved.
Here's a $20.8 trillion moneymaking opportunity
There's a brand-new company that's revolutionizing banking, and is poised to kill the hated traditional bricks-and-mortar banks. That's bad for them, but great for investors. And amazingly, despite its rapid growth, this company is still flying under the radar of Wall Street. To learn more about this company, click here to access our new special free report.
Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.